Physician profile
Jee Young You
NPI 1992246169
$2,530.37
in general payments reported to CMS, 2019-2025
12 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $35.81 · 2024: $1,363 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191 · Travel and Lodging: $982 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.15 |
| Travel and Lodging | $982.05 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,037.51 | 2024 | Single Use Suction Valve (Sterile), Vizishot 2 Flex |
| Glaxosmithkline, LLC. | $443.98 | 2024-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $241.36 | 2025 | Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.27 | 2019-2025 | Ofev, Jascayd |
| Merck Sharp & Dohme LLC | $142.59 | 2025 | Winrevair, Zerbaxa |
| Actelion Pharmaceuticals US, INC. | $80.00 | 2025 | Uptravi, Opsumit |
| Verona Pharma, INC. | $63.02 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $36.25 | 2025 | Dupixent |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.81 | 2020 | |
| United Therapeutics Corporation | $33.69 | 2025 | Tyvaso |
| Viatris Specialty LLC | $16.89 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jee Young You listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.